A Phase Ib/III Study to Evaluating the Efficacy and Safety of Parsaclisib in Combination With Rituximab and Lenalidomide Versus Rituximab in Combination With Lenalidomide in Subjects With Relapsed or Refractory Follicular Lymphoma

A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

开始日期2023-07-28

申办/合作机构

信达生物制药（苏州）有限公司

NCT04796922 / Withdrawn临床3期

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Parsaclisib Plus Investigator's Choice of Either Rituximab or Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus investigator's choice of either rituximab or obinutuzumab versus placebo plus investigator's choice of rituximab or obinutuzumab for the treatment of participants with R/R FL or MZL. The Participants will be stratified in a 1:1 randomization ratio by investigator's choice of rituximab or obinutuzumab prior to randomization, time since last antilymphoma therapy (≤ 2, > 2 years), and disease histology (MZL or FL) .

开始日期2022-12-30

申办/合作机构

Incyte Corp.

CTR20213340 / Terminated临床3期

一项在骨髓纤维化受试者中评价PI3Kδ抑制剂Parsaclisib联合芦可替尼的III期、随机、双盲、安慰剂对照研究

评价并比较parsaclisib+芦可替尼组与安慰剂+芦可替尼组在第24周的脾脏体积。

开始日期2022-05-20

申办/合作机构

信达生物制药（苏州）有限公司

[+2]

100 项与帕萨利司相关的临床结果

登录后查看更多信息

100 项与帕萨利司相关的转化医学

登录后查看更多信息

100 项与帕萨利司相关的专利（医药）

登录后查看更多信息

项与帕萨利司相关的文献（医药）

2024-12-01·AMERICAN JOURNAL OF HEMATOLOGY

Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study

Article

作者: Hanna, Wahid T. ; Rappold, Erica ; Terriou, Louis ; Patriarca, Andrea ; Murakhovskaya, Irina ; DeSancho, Maria T. ; Jäger, Ulrich ; Pane, Fabrizio ; Szeto, Ke ; Leopold, Lance ; Wei, Shaoceng ; Barcellini, Wilma

Abstract:

Autoimmune hemolytic anemia (AIHA) is a group of acquired autoimmune disorders characterized by red blood cell hemolysis. In a phase 2, open‐label, multicenter study, adults with warm AIHA, cold agglutinin disease, or mixed‐type AIHA were administered once‐daily 1.0 or 2.5 mg parsaclisib (selective phosphoinositide 3‐kinase δ inhibitor) orally for 12 weeks, followed by an extension period. Dose increases (for AIHA worsening) or decreases (for tolerability) were permitted. Primary efficacy endpoint was the proportion of patients with complete (≥12 g/dL hemoglobin [Hgb]) or partial (10–12 g/dL Hgb or ≥2 g/dL increase from baseline) response at any visit during weeks 6–12 not attributable to transfusion. Among 25 enrolled patients (median age, 63 y), 16 (64%) achieved a partial or complete Hgb response during weeks 6–12. Responses were observed by week 1 in 52.0% of patients with incremental improvements during weeks 6–12 and sustained responses during the extension period. Responses were higher among patients with warm AIHA versus other types (75.0% vs. 44.4%). Clinically meaningful improvements in Functional Assessment of Chronic Illness Therapy‐Fatigue scores were observed at weeks 6 and 12. All patients had treatment‐emergent adverse events (TEAEs), most commonly diarrhea (32.0%) and pyrexia (28.0%). Grade ≥3 TEAEs occurred in 13 patients (52.0%). TEAEs considered possibly related to treatment occurred in 11 patients (44.0%). No dose reductions were required; six patients (24%) discontinued for a TEAE. In summary, parsaclisib was well tolerated and resulted in substantial improvements in Hgb response at week 1, with durable responses through the extension period.

Clinical trial registration:

This trial was registered at ClinicalTrials.gov (NCT03538041).

2024-06-06·Leukemia & lymphoma

Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)

Article

作者: Cordoba, Raul ; Kumar, Abhijeet ; Langmuir, Peter ; Liu, Teng ; Rappold, Erica ; Abrisqueta, Pau ; Tani, Monica ; Sancho, Juan-Manuel ; Lopez-Guillermo, Armando

Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62.5%, 50.0%, and 50.0% of patients in Treatments A, B, and C, respectively); diarrhea (37.5%) and anemia (31.3%) in Treatment A; abdominal pain, asthenia, diarrhea, and nausea (each 33.3%) in Treatment B; and increased alanine and aspartate aminotransferase (each 37.5%) in Treatment C. Objective responses were observed in 13 patients (81.3%) in Treatment A, 10 (55.6%) in Treatment B, and 8 (50.0%) in Treatment C. Parsaclisib combined with SOC therapies had an expected safety profile and promising efficacy in patients with R/R B-cell lymphomas.

2024-04-01·Pharmacology research & perspectives

Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study

Article

作者: Gong, Xiaohua ; Liu, Xiang ; Liu, Xing ; Li, Jia ; Szeto, Ke ; Chen, Xuejun

Abstract:

Parsaclisib, a potent and selective phosphatidylinositol 3 kinase δ inhibitor, has been investigated for the treatment of B‐cell malignancies and studied in patients with autoimmune diseases and myelofibrosis. The CITADEL‐101 study (NCT02018861) assessed safety, tolerability, and preliminary efficacy of parsaclisib in patients with relapsed or refractory non‐Hodgkin lymphoma. This study evaluated the cardiac safety of parsaclisib as monotherapy based on data from 72 patients enrolled in the CITADEL‐101 study. Time‐matched pharmacokinetic and ECG measurements were collected at specified times for 69 patients receiving monotherapy in doses of 5, 10, 15, 20, 30, and 45 mg once daily. Based on the categorical outlier analysis, no dose‐dependent effect was observed on the incidence of outliers in QT interval corrected for heart rate (HR) by Fridericia's method (QTcF), HR, or cardiac conduction. Based on central tendency analysis, the least square means (LSMs) (90% confidence interval [CI]) of ΔQTcF from the central tendency analysis ranged from −6.83 (−18.8 to 5.19) to 4.75 ms (0.410–9.09) across dose groups (below 20 ms, the threshold of large QT effects) and was not considered dose dependent. Moreover, the LSMs of ΔHR, ΔPR interval, and ΔQRS interval were minor. From the concentration‐ΔQTcF analyses, the predicted ΔQTcF (90% CI) for all dose levels was between 0.365 (−1.75 to 2.48) and 7.87 ms (0.921–14.8), with the highest upper limit of CIs well below 20 ms, and therefore, a large QT/QTc effect was ruled out up to the highest dose level (45 mg) investigated. Overall, parsaclisib at the dose ranges studied did not reveal concentration‐dependent effects on change in QTcF and did not have a significant effect on HR or cardiac conduction.

111

项与帕萨利司相关的新闻（医药）

2024-09-19

·PRNewswire

Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and immunotherapies, such as Bruton's tyrosine kinase (BTK) inhibitors, is improving treatment outcomes and driving market growth for Mantle cell lymphoma. LAS VEGAS, Sept. 19, 2024 /PRNewswire/ -- DelveInsight's ' Mantle Cell Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mantle cell lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mantle cell lymphoma pipeline domain. Key Takeaways from the Mantle Cell Lymphoma Pipeline Report DelveInsight's mantle cell lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for mantle cell lymphoma treatment. Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others are evaluating new mantle cell lymphoma drugs to improve the treatment landscape. Promising mantle cell lymphoma pipeline therapies such as Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle cell lymphoma clinical trials. In May 2024, AstraZeneca had announced positive interim results from the Phase III ECHO clinical trial, which evaluated Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in combination with standard chemoimmunotherapy for treating mantle cell lymphoma (MCL). In March 2024, BeiGene, Ltd. announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting. Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma In October 2023, Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment. The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In January 2023, the FDA granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin lymphoma (NHL), according to an announcement from Lantern Pharma. Request a sample and discover the recent advances in mantle cell lymphoma treatment drugs @ Mantle Cell Lymphoma Pipeline Report The mantle cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mantle cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mantle cell lymphoma clinical trial landscape. Mantle Cell Lymphoma Overview Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by the (11,14) translocation, leading to overexpression of the cyclin D1 (CCND1) gene. Its various morphological variants can make diagnosis challenging, though some cases are straightforward. Many individuals with MCL are asymptomatic in the early stages, but may later seek medical attention due to persistent, typically painless swelling of lymph nodes, especially in the neck and throat region (e.g., Waldeyer's ring). MCL is marked by a reciprocal chromosomal translocation t(11;14)(q13;q32), which places the cyclin D1 gene next to the immunoglobulin heavy chain gene, causing continuous cyclin D1 expression. This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, chromosomal instability, and epigenetic changes. Rarely, MCL cases without this translocation may involve CCND2 or CCND3 translocations. Hypothetical molecular subtypes, based on the cell of origin, correlate with clinical phenotypes: classical or aggressive MCL arises from naive B cells lacking or having limited iGVH mutations and expressing SOX11, a neural transcription factor inhibiting terminal B cell differentiation. The indolent variant originates from antigen-experienced B cells with IGVH somatic hypermutations, typically SOX11-negative and genetically stable. Diagnosis of MCL involves detailed patient history, thorough clinical evaluation, and specialized tests, including biopsy of an affected lymph node or bone marrow. These tests confirm the NHL type and subtype, assess disease extent, and determine appropriate treatments. Treatment for MCL is multifaceted and tailored to each patient, often including chemotherapy, immunotherapy drugs like rituximab, targeted therapies such as ibrutinib, and stem cell transplants, particularly for aggressive disease or younger patients. Radiation therapy may target specific lymphoma areas. Participation in clinical trials can offer new treatment options. Treatment plans are developed collaboratively by healthcare professionals and patients, considering disease stage, overall health, and personal preferences. Regular monitoring and follow-up care are essential to track treatment response and manage side effects effectively. Find out more about mantle cell lymphoma treatment drugs @ Drugs for Mantle Cell Lymphoma Treatment A snapshot of the Mantle Cell Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging mantle cell lymphoma pipeline therapies @ Mantle Cell Lymphoma Clinical Trials Mantle Cell Lymphoma Therapeutics Assessment The mantle cell lymphoma pipeline report proffers an integral view of the mantle cell lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Mantle Cell Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Agammaglobulinemia tyrosine kinase inhibitors Key Mantle Cell Lymphoma Companies: AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others Key Mantle Cell Lymphoma Pipeline Therapies: Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others Dive deep into rich insights for new drugs for mantle cell lymphoma treatment, visit @ Mantle Cell Lymphoma Drugs Table of Contents For further information on the mantle cell lymphoma pipeline therapeutics, reach out @ Mantle Cell Lymphoma Treatment Drugs Related Reports B-Cell Lymphoma Epidemiology B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Pipeline Diffuse Large B-Cell Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期免疫疗法孤儿药

2024-09-16

·PRNewswire

Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight

The competition in follicular lymphoma is rapidly intensifying, with three CAR-T therapies and three bispecific antibodies now approved for relapsed or refractory patients. As both classes of treatments expand, the battle for dominance in this market is growing, with each therapy offering unique advantages in accessibility, efficacy, and safety profiles, setting the stage for a dynamic shift in treatment strategies. LAS VEGAS, Sept. 16, 2024 /PRNewswire/ -- Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL) that develops from B-lymphocytes and is generally slow-growing or indolent. This subtype represents 20–30% of all NHL cases. While follicular lymphoma typically progresses slowly, there are instances where it can grow more rapidly. Treatment options for follicular lymphoma include, chemotherapy, radiation therapy, immunotherapy, stem cell transplantation, CAR T-cell therapy, and bispecific-antibodies. For those in the early stages of the disease (Ann Arbor stages I or II), treatment may involve radiation therapy alone or in combination with chemotherapy. Patients with advanced follicular lymphoma are typically treated initially with a combination of chemotherapy and anti-CD20 antibodies, a method known as chemoimmunotherapy. The most commonly used antibodies are RITUXAN (rituximab) and GAZYVA (obinutuzumab), which specifically target tumor cells associated with follicular lymphoma. In older patients who do not have organ dysfunction, treatment with rituximab alone may be an option. Other therapies like ZEVALIN (yttrium-90 ibritumomab tiuxetan), TAZVERIK (tazemetostat), REVLIMID (lenalidomide), and others are approved for the treatment of follicular lymphoma. CAR T-cell therapies are becoming increasingly significant in treating follicular lymphoma. YESCARTA, a CD19-directed genetically modified autologous T-cell therapy, became the first CAR-T to be approved for follicular lymphoma by the US FDA in March 2021. Before the approval of YESCARTA, BREYANZI was approved in February 2021 for Grade 3B follicular lymphoma that accounts for about 5-10% of all follicular lymphoma cases. Later in April 2022 it was approved by the European commission. In May 2024 BREYANZI was approved for the treatment of relapsed/refractory follicular lymphoma who have received two or more prior lines of systemic therapy and provided sustained clinical benefit with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months. In May 2022, Novartis announced that the European Commission approved KYMRIAH (tisagenlecleucel) for adult patients with relapsed/refractory follicular lymphoma who have undergone two or more systemic therapies. This approval represents the third indication for KYMRIAH, making it the first CAR-T cell therapy sanctioned in Europe for such patients, including those with relapsed/refractory follicular lymphoma Grades 1, 2, and 3A. Additionally, in May 2022, the US FDA granted approval for KYMRIAH for the same patient group. Currently, autologous CAR-T therapies are the only ones approved, but the emerging pipeline predominantly comprises autologous CAR-Ts alongside a growing number of allogeneic CAR-T therapies. Allogeneic CAR-T, a newer term, refers to donor-derived therapies offering several advantages over autologous treatments. These off-the-shelf therapies are readily available, eliminating the need to modify patient cells either at a central manufacturing site or at the point of care. Even though the reimbursement of CAR-T therapies represents a challenge for healthcare providers, insurers, and government agencies, they have successfully reached the majority of the markets by considering the patient pool demand. While determining the cost and reimbursement, various factors, such as pharmacoeconomic analysis and outcome-based responses, as well as the added value to society, have been evaluated. The CAR T-cell-related toxicity, such as the cytokine-release syndrome and neurotoxicity, remain important potential complications of this therapy. Second generation CAR T-cell therapies are emerging with more safety and efficacy to overcome these limitations. If these limitations have been overcome, these are going to be the potential drivers of the market. After CAR-T approval companies focused on developing alternative therapies to overcome CAR-Ts limitations. LUNSUMIO became the first bispecific antibody to get approval for adult patients with relapsed/refractory follicular lymphoma who have undergone two or more lines of systemic treatment in June 2022 in Europe. Later in December 2022, the US FDA approved it for the same indication. This was the game changing step toward a brighter future for follicular lymphoma patients. Bispecific antibodies are ready to use therapies and safer treatment options than CAR-Ts. In 2023, LUNSUMIO captured USD 55 million in revenue in the United States for follicular lymphoma. In the United States, AbbVie and Genmab's epcoritamab, marketed as EPKINLY, first gained FDA approval in May 2023 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This was followed by its approval for follicular lymphoma in June 2024. With the recent FDA authorization for relapsed/refractory follicular lymphoma, along with expected approvals and launches in international markets, EPKINLY is poised to see revenue growth in the coming quarters. Its strong performance in treating relapsed/refractory DLBCL suggests it could achieve similar success in follicular lymphoma. LUNSUMIO now faces competition in the European market for follicular lymphoma, as on August 19, 2024, the European Commission granted approval for the expanded use of AbbVie and Genmab's bispecific antibody, TEPKINLY (epcoritamab), for treating adults with relapsed/refractory follicular lymphoma. The study showed an overall response rate of 83% and a complete response rate of 63%, with the median response duration being 21.4 months. Just after TEPKINLY approval in Europe, Regeneron's ORDSPONO (odronextamab) a CD20 x CD3 bispecific antibody approved by European Commission on August 26, 2024 for the treatment of adult patients with relapsed/refractory follicular lymphoma or relapsed/refractory DLBCL, after two or more lines of systemic therapy. After this approval, ORDSPONO becomes the first off-the-shelf option that can be administered in the out-patient setting. In March 2024, the US FDA declined approval for odronextamab for treating follicular lymphoma and DLBCL. The agency issued two complete response letters concerning the biologics license application (BLA) for odronextamab in relapsed/refractory follicular lymphoma and DLBCL after two or more lines of systemic therapy. The denial was tied to the enrollment status of confirmatory trials assessing the drug. Importantly, there were no concerns raised about odronextamab's efficacy, safety, trial design, labeling, or manufacturing. Both EPKINLY, LUNSUMIO, and ORDSPONO are off-the-shelf therapies, offering greater accessibility compared to CD19 CAR-T treatments. These drugs will compete not only with each other but also with CAR-T therapies to secure a substantial portion of the follicular lymphoma market. Learn more about the FDA-approved follicular lymphoma drugs @ Drugs for Follicular Lymphoma Treatment A new class has also emerged for the treatment of follicular lymphoma, i.e., Bruton tyrosine kinase (BTK) inhibitors. In November 2023, BeiGene received approval from the European Commission for BRUKINSA (zanubrutinib) to treat relapsed/refractory follicular lymphoma. Later in March 2024, the US FDA approved BRUKINSA for the same indication. BRUKINSA is the first and only BTK inhibitor approved for this condition. To know more about follicular lymphoma treatment options, visit @ New Treatment for Follicular Lymphoma The follicular lymphoma pipeline is robust with so many companies working in the domain. Various potential therapies that are projected to enter during the forecast period include AbbVie's IMBRUVICA, Xynomic Pharmaceuticals' Abexinostat, Pfizer PF-06821497, Incyte's Parsaclisib, Bristol-Myers Squibb's Nivolumab, and others. Discover which therapies are expected to grab major follicular lymphoma market share @ Follicular Lymphoma Market Report IMBRUVICA (ibrutinib) is an anti-cancer medication available in various forms, including hard gelatin capsules, tablets, film-coated tablets, and oral suspension. It is being developed by AbbVie and is currently undergoing Phase III trials for follicular lymphoma. This study aims to determine if adding ibrutinib to the treatment will extend progression-free survival (PFS) compared to using rituximab alone in patients with newly diagnosed follicular lymphoma. Xynomic Pharmaceuticals is developing Abexinostat for treating follicular lymphoma. The company is currently testing this investigational drug in a Phase II clinical trial involving patients with relapsed/refractory follicular lymphoma who have received at least three prior therapies. The US FDA has granted Abexinostat fast-track designation for this use. In June 2021, Xynomic completed a short-form merger with Xu-Nuo Pharma in a "Going Private" transaction. Post-merger, Xu-Nuo Pharma will continue Xynomic's business as its main focus. Discover more about drugs for follicular lymphoma in development @ Follicular Lymphoma Clinical Trials The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for follicular lymphoma is expected to grow from USD 1.4 billion in 2020 with a significant CAGR by 2034. This growth can be attributed to the introduction of upcoming therapies and the rise in the increasing incidence of follicular lymphoma. DelveInsight's latest published market report titled as Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the follicular lymphoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The follicular lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of Follicular Lymphoma Risk-specific Incident Cases of Follicular Lymphoma Stage-specific Incident Cases of Follicular Lymphoma Mutation-specific Incident Cases of Follicular Lymphoma Transplant Eligible and Ineligible Patient Pool of Follicular Lymphoma Refractory/Relapsed Incident Cases of Follicular Lymphoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM follicular lymphoma market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis up to 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this follicular lymphoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the follicular lymphoma market. Also, stay abreast of the mitigating factors to improve your market position in the follicular lymphoma therapeutic space. Related Reports Follicular Lymphoma Pipeline Follicular Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc, Allogene Therapeutics, MEI Pharma, Innovent Biologics, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期免疫疗法上市批准快速通道临床3期

2024-08-13

·研发客

让信达恒瑞受挫的PI3K，何去何从？| 第一现场

// • FDA 2022年ODAC会议主张采用随机对照试验而非单臂试验作为血液瘤中PI3K抑制剂的申报依据； • PI3K抑制剂基于单臂试验获批仍有可能； • 安全问题在PI3K抑制剂中受到特别关注； • PI3K抑制剂与其他疗法联合应用值得进一步探索。近来PI3K抑制剂再次引起热议。今年6月，恒瑞医药林普利塞片的新适应症上市申请出现在药监局药品通知件中，意味着未获批准。该药成为继信达生物帕萨利司和正大天晴TQ-B3525片之后，第三款在中国上市受挫的PI3K抑制剂。根据公开资料，这三项上市申请均基于单臂2期研究数据，其中林普利塞申报适应症为外周T细胞淋巴瘤（PTCL），后两者申报的则是滤泡性淋巴瘤（FL）。 “这可能是CDE参考了FDA的立场。”阿诺医药研发负责人谢毅钊博士在接受研发客采访时表示，“过去多款PI3Kδ抑制剂曾基于单臂试验中的ORR数据获批用于血液瘤，后又主动或被动撤回这些适应症。FDA已在2022年召开的肿瘤咨询委员会（ODAC）会议中指出，这些高水平的ORR并不一定最终能带来OS获益，并主张采用随机对照试验（RCT）而非单臂试验作为血液瘤中PI3K抑制剂的申报依据。” 海和药物副总裁张毅翔博士认为：“林普利塞、帕萨利司与TQ-B3525均靶向PI3Kδ，且申报适应症同为血液瘤。2022年ODAC会议中的共识可能会对此类产品有一定的影响”，“FL和PTCL适应症对应线数患者人群中，国内已获批药物的疗效和安全性也会对后续产品的审评带来一定影响。” 阿诺医药与海和药物均是PI3K抑制剂研发赛道的一员。前者正在全球开展泛PI3K抑制剂buparlisib治疗头颈部鳞状细胞癌（HNSCC）的多中心3期临床，目前已完成全部患者入组；后者的PI3Kα选择性抑制剂CYH33拟用于多种实体瘤等，针对复发/持续性卵巢、输卵管或原发性腹膜透明细胞癌的研究已进入2期临床阶段，在HR+/HER2-、PIK3CA突变的晚期乳腺癌患者中的研究即将进入3期关键临床阶段。据研发客不完全统计，曾参与研发PI3K抑制剂的中国公司有近20家，但其中近一半产品被搁置，有些甚至已剔除出公司管线。仍在开发的产品则以实体瘤适应症为主。左右滑动查看还能考虑单臂试验吗？随着药监局审评要求收紧，未来单臂临床试验用于支持PI3K抑制剂上市还有希望吗？张毅翔给出的答案是肯定的。 “FDA并不是对所有PI3K抑制剂的单臂试验说不。2022年FDA召开的ODAC会议共识仅限于PI3K抑制剂在血液瘤中的应用，如果新一代PI3K抑制剂表现出强效低毒的特征，也并不一定会受限于上述共识。此外，ODAC会议中也进行了澄清，FDA批准的PI3Kα抑制剂alpelisib，并不在会议讨论范围。”她说。早在2019年5月，alpelisib就获得FDA批准用于HR+/HER2-携带PIK3CA突变的晚期转移性乳腺癌，成为首个获批实体瘤的PI3K抑制剂。2022年4月，该药又基于真实世界研究数据获得FDA加速批准，用于PIK3CA相关过度生长综合症（PROS）成人和2岁及以上儿童患者。那么，什么样的PI3K抑制剂能够凭借单臂临床试验数据获批上市？ “这需要满足监管机构关于单臂试验的相关指导原则，能解决未满足的临床需求且获益风险比高的药物仍会有机会。”张毅翔表示。根据指导原则，单臂试验支持药物上市适用于患者无有效治疗选择，试验药物机制明确、疗效突出、安全性风险可控，对照组疗效数据明确，罕见病的情况。拓展阅读 CDE收紧单臂临床试验申请回过头来看国内上市受挫的三款PI3K抑制剂，它们的遭遇或许早已有迹可循。尤其在已有3款PI3K抑制剂获批的FL领域，后来者想要基于单臂试验获批的可能性几乎为零。即便花大力气完成确证性3期研究并获批，未来产品的商业化价值也要重新考量。数据显示，FL约占所有非霍奇金淋巴瘤（NHL）病例的10%～20%，中国每年新发病例不足2万。 “虽然FL是一个小众适应症，但如果产品可以做到全球前三，机会还是有的。如果不是，在竞争对手的先发优势下，后来者几乎没什么潜力，尤其在中国，新药的价格和利润都很低。”谢毅钊说。信达生物也曾在2023年9月发布的公告中提到，其帕萨利司申报的r/r FL适应症患者群体较小、市场竞争较为激烈。基于产品价值等多方考虑后，该公司决定主动撤回该产品在中国的上市申请。如何克服毒性问题一直以来，安全问题在PI3K抑制剂开发中受到特别关注，一些产品上市便伴有多项黑框警告，严重且致命的不良反应还会令患者OS受损。在谢毅钊看来，“PI3K抑制剂大部分的毒性都是On-target off-tumor（非肿瘤靶向毒性），这很难避免。” 因为PI3K信号通路在许多正常细胞中扮演着重要角色，参与调节细胞的增殖、凋亡与分化等生理过程。并且，不同PI3K家族成员有不同的生理作用，针对不同亚型的选择性抑制剂，在副作用方面也有很大不同。比如PI3Kδ的毒性偏向于肝毒性和胃肠道反应，PI3Kα偏向高血糖和皮肤反应等。但这并不意味着PI3K抑制剂的终结。以阿诺医药为例，虽然知晓buparlisib在乳腺癌试验中因高毒性被诺华放弃，但公司仍引进该产品，之后将研发方向聚焦于HNSCC。 “HNSCC是一个临床需求严重未满足的治疗领域，患者在接受PD-1/L1抑制剂治疗后几乎没有其它标准治疗方法，他们的需求更多是延长生命，因此对新药毒性的容忍度比较高。相比之下，乳腺癌患者对毒性的接受度低很多，很多人经过多种治疗后已经能够正常工作与生活。”谢毅钊说。拓展阅读阿诺医药：收购诺华PI3K抑制剂并非孤注一掷谁能改变全球头颈鳞癌治疗格局海和药物的策略则是聚焦药物有竞争力的适应症，并进行稳健的剂量探索，确定临床获益风险比最佳剂量。 “FDA ODAC会议中已指出，PI3Kδ抑制剂在血液肿瘤的开发中存在剂量探索不足的问题，这也可能是导致OS受损的原因。因此，需要通过稳健的剂量探索来确定在不同的适应症、不同的药物联用情况下获益风险平衡比最佳的剂量。”张毅翔说。她同时还提到，突变型PI3K亚型选择性抑制剂的开发也可能解决靶点相关的毒性问题，但其疗效还需等待临床试验的验证。未来的研发方向事实上，不同亚型的PI3K抑制剂潜在获益人群也有所不同，比如PI3Kα抑制剂治疗该靶点相关突变的肿瘤、泛PI3K抑制剂治疗头颈癌、PI3Kδ/γ抑制剂治疗淋巴瘤、PI3Kβ抑制剂治疗前列腺癌等。其中，受访者最看好的当属PI3Kα。研究表明，编码PI3Kα催化亚基的PIK3CA基因是癌症中最常见的突变基因之一，该突变在多种恶性肿瘤中均有发现且比例较高（约10%~40%）。因此PI3Kα抑制剂可用于治疗PIK3CA基因突变驱动的多种实体瘤，适应症更为广泛。当下，首款PI3Kα抑制剂alpelisib不仅斩获乳腺癌和PROS适应症，而且取得商业化成功。诺华财报显示，该产品2023年全球销售额达到5亿美元，同比增长35%。另一款来自罗氏的PI3Kα抑制剂inavolisib（伊那利塞）也已在3期临床中取得积极结果，其联合CDK4/6抑制剂哌柏西利和雌激素受体拮抗剂氟维司群，可将一线PIK3CA突变乳腺癌患者的PFS翻倍。在张毅翔看来：“PI3Kα抑制剂与其它抗肿瘤药物的联合用药是未来开发的重要方向之一，尤其与免疫疗法的联用值得探索。” 采访中，谢毅钊同样提及联合用药的概念。 “一直以来，PI3K抑制剂单药治疗面临较大的挑战，这可能与系统的反馈机制有关。当PI3K的活性受到抑制时，系统其它信号通路会很快将其回调至原有水平，这也是过去很多PI3K抑制剂疗效不足的原因。”他进一步表示，“未来，PI3K抑制剂与其它针对不同信号通路的产品联用更有可能成功，比如与免疫检查点抑制剂的联合使用，或者开发双靶点抑制剂，不过前提是两个靶点之间不能存在毒性的重叠。” 编辑 | 姚嘉 yao.jia@PharmaDJ.com 总第2177期访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com

申请上市临床2期临床3期

100 项与帕萨利司相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11437	-	-	DB14867

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性滤泡性淋巴瘤	申请上市	中国	Quotient Sciences Ltd.	2023-01-06
复发性滤泡性淋巴瘤	申请上市	中国	信达生物制药（苏州）有限公司	2023-01-06
复发性滤泡性淋巴瘤	申请上市	中国	Incyte Corp.	2023-01-06
难治性滤泡性淋巴瘤	申请上市	中国	Incyte Corp.	2023-01-06
难治性滤泡性淋巴瘤	申请上市	中国	Quotient Sciences Ltd.	2023-01-06
难治性滤泡性淋巴瘤	申请上市	中国	信达生物制药（苏州）有限公司	2023-01-06
滤泡性淋巴瘤	申请上市	美国	Incyte Corp.	2021-11-01
套细胞淋巴瘤	申请上市	美国	Incyte Corp.	2021-11-01
边缘区B细胞淋巴瘤	申请上市	美国	Incyte Corp.	2021-11-01
自身免疫性溶血性贫血	临床3期	美国	Incyte Corp.	2022-03-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Parsaclisib plus R-CHOP	艱蓋蓋製鹽積獵襯淵衊(構鹽夢窪淵襯醖鬱積觸) = 71.4% vs 16.3% 觸窪鹽糧網鹽鑰壓觸糧 (鏇衊積膚壓淵網餘選膚 ) 更多	-	2024-12-08
				Parsaclisib plus Pola-R-CHP
NCT03538041 (Pubmed \| Am J Hematol) 人工标引	临床2期	免疫性溶血性贫血	25	Parsaclisib	(糧膚糧選選網憲淵繭鏇) = 繭齋製鑰醖鏇齋鑰選網壓鹽壓獵鑰夢積蓋鹽選 (鹹獵壓築衊鹽鹽鏇醖獵 ) 更多	积极	2024-10-22
NCT04551066 (CTgov)	临床3期	原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 \| 原发性骨髓纤维化	252	Parsaclisib+Ruxolitinib (Parsaclisib Plus Ruxolitinib)	網憲製齋鹽製衊糧淵鑰(築獵構構網襯淵壓築範) = 壓廠廠齋製廠淵壓觸獵鹹廠糧築艱鬱選網齋積 (願觸遞積鑰遞獵繭窪範, 範夢醖觸構膚膚齋襯鑰 ~ 構窪醖鑰餘夢鹹齋壓艱) 更多	-	2024-10-04
				Placebo+Ruxolitinib (Placebo Plus Ruxolitinib)	網憲製齋鹽製衊糧淵鑰(築獵構構網襯淵壓築範) = 齋蓋範襯繭觸膚糧糧築鹹廠糧築艱鬱選網齋積 (願觸遞積鑰遞獵繭窪範, 選繭鏇選顧鑰襯願製淵 ~ 選膚膚選餘艱糧鏇齋鬱) 更多
NCT04551053 (CTgov)	临床3期	原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 \| 原发性骨髓纤维化	177	Parsaclisib+Ruxolitinib (Parsaclisib Plus Ruxolitinib)	鹽艱顧積糧糧鏇積鏇遞(艱艱蓋顧膚襯繭觸鹹壓) = 獵醖範蓋廠鹽構獵鏇鏇觸選範選遞艱膚願淵蓋 (窪壓觸醖獵構衊齋願鏇, 鹹壓壓鹹築艱鏇餘網積 ~ 齋願鹹淵艱積繭廠範積) 更多	-	2024-08-23
				Placebo+Ruxolitinib (Placebo Plus Ruxolitinib)	鹽艱顧積糧糧鏇積鏇遞(艱艱蓋顧膚襯繭觸鹹壓) = 醖鑰築鏇襯築獵觸淵鏇觸選範選遞艱膚願淵蓋 (窪壓觸醖獵構衊齋願鏇, 淵獵製餘蓋膚膚壓糧廠 ~ 築衊製簾糧築範鏇鹽遞) 更多
NCT02718300 (Pubmed) 人工标引	临床2期	骨髓纤维化追加	74	Parsaclisib 10 or 20 mg+ruxolitinib	膚窪餘憲淵蓋繭淵鏇憲(夢淵衊鬱鏇醖糧觸簾鑰) = 艱艱壓壓選製襯獵淵衊衊願遞願製壓鬱簾蓋繭 (齋艱蓋糧襯簾願鏇範蓋 )	积极	2024-03-26
				Parsaclisib 5 or 20 mg+ruxolitinib	膚窪餘憲淵蓋繭淵鏇憲(夢淵衊鬱鏇醖糧觸簾鑰) = 築衊簾獵鏇淵糧餘獵獵衊願遞願製壓鬱簾蓋繭 (齋艱蓋糧襯簾願鏇範蓋 )
NCT04434937 (CTgov)	临床2期	滤泡性淋巴瘤	42	Parsaclisib	鹹觸獵淵壓築顧鑰襯選(遞襯鹹範遞鑰範壓遞襯) = 醖衊遞鹹鏇積廠蓋鑰窪鹹襯繭鑰夢膚網鏇淵齋 (繭壓簾鹽襯膚夢壓淵壓, 憲顧鹽遞壓糧膚鹽襯鑰 ~ 鹽築餘襯淵鑰鏇餘範憲) 更多	-	2024-01-03
NCT02646748 (Pubmed \| Cancer Res Commun)	临床1期	晚期恶性实体瘤	159	Itacitinib	艱鹹獵蓋鬱繭鹽廠繭選(築襯鑰淵獵鏇窪壓窪糧) = Most common itacitinib treatment-related adverse events (TRAE) were fatigue, nausea, and anemia. 積糧鹽襯蓋製積窪衊選 (範網構鹹糧構鬱鹽遞獵 ) 更多	不佳	2023-12-19
				Parsaclisib
NCT04298879 (EHA2023)	临床2期	难治性滤泡性淋巴瘤	61	Parsaclisib 20 mg	醖築齋顧蓋構襯顧鏇膚(蓋憲構觸鬱鏇餘廠願顧) = 鏇顧齋鑰齋鏇顧遞夢淵積選壓積築襯積鑰艱襯 (蓋積製鬱顧醖醖膚夢衊, 82.7 ~ 97.6) 更多	-	2023-06-08
NCT02718300 (INCB50465-201, SOHO2022)	临床2期	骨髓纤维化追加 platelet count	67	Parsaclisib 10 mg QD	繭鹽憲遞鹽鹽遞壓繭襯(醖繭繭積醖積積簾襯獵) = 糧憲廠齋鹽淵衊壓鹹餘簾蓋選遞鹽夢廠築餘窪 (齋鹽範願顧淵鏇窪獵夢 ) 更多	积极	2022-10-01
				Parsaclisib 20 mg QD	繭鹽憲遞鹽鹽遞壓繭襯(醖繭繭積醖積積簾襯獵) = 蓋築鹹顧襯鹽網艱餘醖簾蓋選遞鹽夢廠築餘窪 (齋鹽範願顧淵鏇窪獵夢 ) 更多
NCT03538041 (phase 2, open‐label study, CTgov)	临床2期	自身免疫性溶血性贫血	25	Parsaclisib (Parsaclisib 1 mg QD)	壓簾願觸範鹽廠餘遞窪(願壓醖壓觸選繭觸觸廠) = 築憲鏇餘蓋糧積襯壓憲獵夢醖鬱網鏇鑰膚鹹鏇 (齋遞鹽遞壓網獵淵蓋獵, 顧鑰繭壓糧觸醖顧鑰簾 ~ 衊繭簾範糧願鹽選觸構) 更多	-	2022-09-22
				Parsaclisib (Parsaclisib 2.5 mg QD)	壓簾願觸範鹽廠餘遞窪(願壓醖壓觸選繭觸觸廠) = 夢壓夢簾壓醖網顧範糧獵夢醖鬱網鏇鑰膚鹹鏇 (齋遞鹽遞壓網獵淵蓋獵, 夢願製衊壓憲淵鬱夢鹽 ~ 襯繭積膚鑰廠憲繭繭夢) 更多